Market Access/ News/ News AbbVie files Vraylar as add-on therapy for depression in US Phil Taylor AbbVie, depression, Psychiatry, regulatory, Vraylar 0 Comment AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include Share X AbbVie files Vraylar as add-on therapy for depression in US https://pharmaphorum.com/news/abbvie-files-vraylar-as-add-on-therapy-for-depression-in-us/
AbbVie, depression, Psychiatry, regulatory, Vraylar
0 Comment
